• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建模骨转移患者的癌症结局:通过联合模型将生存数据与 I 型胶原 N-端肽(NTX)动力学相结合。

Modelling cancer outcomes of bone metastatic patients: combining survival data with N-Telopeptide of type I collagen (NTX) dynamics through joint models.

机构信息

INESC-ID, Instituto Superior Técnico, Universidade de Lisboa, Rua Alves Redol, 9, Lisboa, 1000-029, Portugal.

IDMEC, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, Lisboa, 1049-001, Portugal.

出版信息

BMC Med Inform Decis Mak. 2019 Jan 17;19(1):13. doi: 10.1186/s12911-018-0728-1.

DOI:10.1186/s12911-018-0728-1
PMID:30654776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6337820/
Abstract

BACKGROUND

Joint models (JM) have emerged as a promising statistical framework to concurrently analyse survival data and multiple longitudinal responses. This is particularly relevant in clinical studies where the goal is to estimate the association between time-to-event data and the biomarkers evolution. In the context of oncological data, JM can indeed provide interesting prognostic markers for the event under study and thus support clinical decisions and treatment choices. However, several problems arise when dealing with this type of data, such as the high-dimensionality of the covariates space, the lack of knowledge about the function structure of the time series and the presence of missing data, facts that may hamper the accurate estimation of the JM.

METHODS

We propose to apply JM for the analysis of bone metastatic patients and infer the association of their survival with several covariates, in particular the N-Telopeptide of Type I Collagen (NTX) dynamics. This biomarker has been identified as a relevant prognostic factor in patients with metastatic cancer, but only using static information in some specific time points.

RESULTS

We extended this analysis using the full NTX time series for a larger cohort of patients with bone metastasis, and compared the results obtained by the JM and the extended Cox regression model. Imputation based on fuzzy clustering was used to deal with missing values and several functions for NTX evolution were compared, such as rational, exponential and cubic splines.

CONCLUSIONS

The JM obtained confirm the association between NTX values and patients' response, attesting the importance of this time series, and additionally provide a deep understanding of the key survival covariates.

摘要

背景

联合模型 (JM) 已成为一种很有前途的统计框架,可以同时分析生存数据和多个纵向响应。这在临床研究中尤为相关,研究目的是估计时间事件数据与生物标志物演变之间的关联。在肿瘤学数据的背景下,JM 确实可以为研究中的事件提供有趣的预后标志物,从而支持临床决策和治疗选择。然而,在处理这类数据时会出现几个问题,例如协变量空间的高维性、对时间序列函数结构的了解不足以及存在缺失数据,这些事实可能会阻碍 JM 的准确估计。

方法

我们提出应用 JM 分析骨转移患者,并推断他们的生存与多个协变量的关联,特别是 I 型胶原 N-端肽 (NTX) 动力学。这种生物标志物已被确定为转移性癌症患者的一个相关预后因素,但仅在某些特定时间点使用静态信息。

结果

我们使用更大的骨转移患者队列扩展了对 NTX 全时间序列的分析,并比较了 JM 和扩展的 Cox 回归模型获得的结果。使用基于模糊聚类的插补处理缺失值,并比较了 NTX 演化的几种函数,例如有理、指数和三次样条。

结论

获得的 JM 证实了 NTX 值与患者反应之间的关联,证明了这个时间序列的重要性,并且还提供了对关键生存协变量的深入理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/f4d32b4abf6e/12911_2018_728_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/131d9d5cb334/12911_2018_728_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/8fbbbe35ad93/12911_2018_728_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/281b87775d5d/12911_2018_728_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/95667cd6053b/12911_2018_728_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/97feb1cf72f7/12911_2018_728_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/f4d32b4abf6e/12911_2018_728_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/131d9d5cb334/12911_2018_728_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/8fbbbe35ad93/12911_2018_728_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/281b87775d5d/12911_2018_728_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/95667cd6053b/12911_2018_728_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/97feb1cf72f7/12911_2018_728_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/117d/6337820/f4d32b4abf6e/12911_2018_728_Fig6_HTML.jpg

相似文献

1
Modelling cancer outcomes of bone metastatic patients: combining survival data with N-Telopeptide of type I collagen (NTX) dynamics through joint models.建模骨转移患者的癌症结局:通过联合模型将生存数据与 I 型胶原 N-端肽(NTX)动力学相结合。
BMC Med Inform Decis Mak. 2019 Jan 17;19(1):13. doi: 10.1186/s12911-018-0728-1.
2
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.I型胶原N-端肽在乳腺癌骨转移患者中的长期动态变化:临床结局及骨外转移的影响
Oncologist. 2016 Dec;21(12):1418-1426. doi: 10.1634/theoncologist.2015-0527. Epub 2016 Aug 17.
3
Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.基线血清NTx水平对仅发生骨转移的转移性乳腺癌患者具有预后价值。
Ann Oncol. 2004 Mar;15(3):455-9. doi: 10.1093/annonc/mdh089.
4
Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients.前列腺癌患者尿I型胶原交联N端肽水平与骨闪烁显像结果的相关性
Metabolism. 2002 Jul;51(7):814-8. doi: 10.1053/meta.2002.33344.
5
[Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].[I型胶原交联N-端肽(NTx)作为前列腺癌患者骨转移标志物的临床应用——与血清PICP、PINP和ICTP的比较]
Hinyokika Kiyo. 2000 Dec;46(12):869-72.
6
Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.血清I型前胶原氨基端前肽作为肺癌骨转移潜在诊断标志物的Meta分析
PLoS One. 2017 Nov 28;12(11):e0187860. doi: 10.1371/journal.pone.0187860. eCollection 2017.
7
A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.一项针对前列腺癌患者,使用骨闪烁扫描术对比研究前列腺特异性抗原(PSA)、I型前胶原C端前肽(PICP)和尿I型胶原交联N端肽(NTx)水平的研究。
Ann Nucl Med. 2003 Jun;17(4):297-303. doi: 10.1007/BF02988524.
8
Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.血清Ⅰ型胶原交联 N 末端肽作为非小细胞肺癌预后标志物的临床意义。
Clin Lung Cancer. 2013 Jan;14(1):50-4. doi: 10.1016/j.cllc.2012.03.012. Epub 2012 May 18.
9
Can bone markers guide more effective treatment of bone metastases from breast cancer?骨标志物能否指导更有效地治疗乳腺癌骨转移?
Breast Cancer Res Treat. 2006 May;97(1):81-90. doi: 10.1007/s10549-005-9094-7. Epub 2005 Dec 1.
10
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.唑来膦酸与骨转移及破骨细胞活性标志物升高的乳腺癌患者的生存情况
Oncologist. 2007 Sep;12(9):1035-43. doi: 10.1634/theoncologist.12-9-1035.

引用本文的文献

1
Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR breast cancer patients undergoing CDK4/6 treatment.纵向肿瘤分数轨迹可预测接受 CDK4/6 治疗的转移性 HR 乳腺癌患者的进展风险。
Mol Oncol. 2021 Sep;15(9):2390-2400. doi: 10.1002/1878-0261.12870. Epub 2020 Dec 18.
2
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview.原发灶不明的骨转移:生物学特征与临床概述
Cancers (Basel). 2019 Aug 29;11(9):1270. doi: 10.3390/cancers11091270.

本文引用的文献

1
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?骨转移的分子机制:哪些靶点从实验室走向了临床?
Int J Mol Sci. 2016 Aug 27;17(9):1415. doi: 10.3390/ijms17091415.
2
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.I型胶原N-端肽在乳腺癌骨转移患者中的长期动态变化:临床结局及骨外转移的影响
Oncologist. 2016 Dec;21(12):1418-1426. doi: 10.1634/theoncologist.2015-0527. Epub 2016 Aug 17.
3
Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification.
纵向数据与生存数据的联合建模:纳入延迟进入及模型误设评估
Stat Med. 2016 Mar 30;35(7):1193-209. doi: 10.1002/sim.6779. Epub 2015 Oct 29.
4
Bone remodeling markers and bone metastases: From cancer research to clinical implications.骨重塑标志物与骨转移:从癌症研究到临床意义
Bonekey Rep. 2015 Apr 22;4:668. doi: 10.1038/bonekey.2015.35. eCollection 2015.
5
Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.评估纵向数据与生存数据联合模型中的模型拟合及其在癌症临床试验中的应用。
Stat Med. 2014 Nov 30;33(27):4715-33. doi: 10.1002/sim.6269. Epub 2014 Jul 20.
6
Consensus on the utility of bone markers in the malignant bone disease setting.恶性骨病中骨标志物的应用共识。
Crit Rev Oncol Hematol. 2011 Dec;80(3):411-32. doi: 10.1016/j.critrevonc.2011.02.005. Epub 2011 Mar 15.
7
Fuzzy c-means clustering of incomplete data.不完整数据的模糊 c 均值聚类
IEEE Trans Syst Man Cybern B Cybern. 2001;31(5):735-44. doi: 10.1109/3477.956035.
8
Joint models for multivariate longitudinal and multivariate survival data.多变量纵向数据和多变量生存数据的联合模型。
Biometrics. 2006 Jun;62(2):432-45. doi: 10.1111/j.1541-0420.2005.00448.x.
9
A flexible B-spline model for multiple longitudinal biomarkers and survival.一种用于多个纵向生物标志物和生存情况的灵活B样条模型。
Biometrics. 2005 Mar;61(1):64-73. doi: 10.1111/j.0006-341X.2005.030929.x.
10
A Bayesian semiparametric joint hierarchical model for longitudinal and survival data.一种用于纵向数据和生存数据的贝叶斯半参数联合分层模型。
Biometrics. 2003 Jun;59(2):221-8. doi: 10.1111/1541-0420.00028.